- Home
- EVAX
EVAX
Evaxion Biotech
as 08-22-2025 4:00pm EST
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.1M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 95.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $17.75 | Next Earning Date: | 08-14-2025 |
| Revenue: | $3,176,000 | Revenue Growth: | 1042.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Evaxion Biotech News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
Zacks Small Cap Research
2 months ago
EVAX AI Technology Produces New Vaccine Candidate
MT Newswires
2 months ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
2 months ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GlobeNewswire
3 months ago
Evaxion receives grant funding to design new polio vaccine
Zacks Small Cap Research
3 months ago
EVAX: Grant Illustrates Belief in Technology
GuruFocus.com
3 months ago
Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...
GlobeNewswire
3 months ago
Evaxion announces business update and first quarter 2025 financial results
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.